Screener
Kailera Therapeutics KLRA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Series B convertible preferred stock: $0.00001 par value; 43,084,539 shares authorized at March 31, 2026 and December 31, 2025; 43,084,539 shares issued and outstanding at March 31, 2026 and December 31, 2025; liquidation value of $603.2 million at March 31, 2026 | 602,058 | 602,058 |
| Stockholders’ deficit: | ||
| Common stock, $0.00001 par value; 105,384,000 shares authorized at March 31, 2026 and December 31, 2025; 29,953 and 19,048 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 15,977 | 11,981 |
| Accumulated other comprehensive (loss) income | (532) | 229 |
| Accumulated deficit | (447,533) | (368,668) |
| Total stockholders’ deficit | (432,088) | (356,458) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $624,756 | $692,294 |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's total liabilities & equity?
- Kailera Therapeutics (KLRA) reported total liabilities & equity of $624.76M in Q1 2026.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Kailera Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude